Product Description
DRL-17822 is a Cholesteryl Ester Transfer Protein (CETP) Inhibitor being tested in the treatment of Patients With Abnormal Cholesterol Levels. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01388816?term=DRL-17822&draw=2&rank=1)
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: DR. REDDY'S LABORATORIES LIMITED
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hyperlipoproteinemia Type II|Hyperlipidemia|Hyperlipoproteinemias
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01388816 |
DRL-17822/CD/004 | P2 |
Completed |
Hyperlipoproteinemias|Hyperlipoproteinemia Type II|Hyperlipidemia |
2012-05-01 |
2019-03-19 |
||
2011-001023-21 |
2011-001023-21 | P2 |
Completed |
Hyperlipidemia |
2012-04-10 |
2022-03-13 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|